Autologous hematopoietic stem cell transplantation (AHSCT) has been proven as the best therapeutic approach for selected patients (pts) with refractory/relapsed Hodgkin lymphoma (HL) more than 25 years ago. Nevertheless, the optimal conditioning regimen still remains debatable.

We herein present the outcome of 30 pts (11 females, 19 males), aged of a median 30 (16-76) years, underwent AHSCT for primary refractory (14 pts) or relapsed (16 pts: 11 late, 5 early) HL, with a single agent conditioning regimen consisted of high dose Melphalan (HD-MPH: 200 mg/m^2^). In 17 patients, the histological diagnosis was compatible with nodular sclerosis, in 6 with mixed cellularity and in 2 with lymphocyte predominance type, while in 5 was unspecified. After a median of 3 (1-6) cycles of salvage treatment, 15 pts proceeded to AHSCT in complete metabolic remission (CMR) according to PET/CT criteria, 5 in very good partial remission (VGPR:  ≥ 75% response) and 10 in PR (\>50% and \<75% response). The median interval time from documentation of disease refractoriness to AHSCT was 4 (2-66) months. Twenty-four hours after HD-MPH administration, a median number of 6, 7 (2, 8-11)  × 10^6^/kg CD34+ cells were infused. The engraftment was successful and rapid for all the patients: neutrophils reached \>1000/mm^3^ after a median of 12 (10-13) days and platelets \>20000/mm^3^ after a median of 14 (10-17) days. In a median follow up of 22 (2-68) months, 27 patients are alive while 21 are progression free. Three patients died; 2, due to disease progression and 1 during the early post AHSCT period, because of MERS-CoV pneumonia. No other major toxicity (WHO \> 3) was noticed in the peri- or early-AHSCT period.

The 5-yr overall survival (OS) and progression free survival (PFS) are 85% and 60%, respectively. According to the disease status before AHSCT, the 5ys-OS rates were 93% vs. 77% (p = ns) for patients in CMR/VGPR and PR respectively, while the 5ys-PFS was similar for both groups (60%).

Two patients aged of 63 and 55 ys, heavily pretreated (3 & 5 cycles of salvage treatment), experienced secondary MDS, 2, 5 and 1, 5 years post AHSCT respectively. Currently are alive, on specific treatment and supportive care.

Our results of AHSCT with conditioning regimen of HD-MPH for HL pts, are in line with the limited published studies. The long-term OS and PFS rates of 85% and 60% are at least comparable with the results of AHSCTs using multiagent conditioning regimens in terms of safety and efficacy, offering additionally the advantage of cost effectiveness and less exposure to multiple chemotoxic agents. However, randomized trials with large series of patients and prolonged follow-up are needed to substantiate the optimal preparative regimen in AHSCT for refractory/relapsed HL.
